Current management and risk of recurrent stroke in cerebrovascular patients with right-to-left cardiac shunt

Cerebrovasc Dis. 2009;28(4):349-56. doi: 10.1159/000229553. Epub 2009 Jul 24.

Abstract

Background: Right-to-left cardiac shunt (RLS) is considered a risk factor for stroke, especially in patients aged <55 years. We aimed to investigate the current management and prognosis in consecutive patients with RLS and otherwise cryptogenic cerebrovascular events.

Methods: In total, 1,126 patients with cryptogenic stroke or TIA were included from 17 German neurology departments. During a mean follow-up of 28.4 months, we assessed current antithrombotic medication, percutaneous device closure (PDC) and recurrent cerebrovascular events in 899 patients (79.8%). Stroke recurrence was compared between 548 patients without RLS and 351 patients with RLS under various prevention regimens.

Results: RLS was detected in 35.9% of cryptogenic cerebrovascular patients, but could not be evaluated as an independent predictor for recurrent stroke (adjusted HR 1.6, 95% CI: 0.9-2.7). In RLS-positive patients, the Kaplan-Meier estimate for stroke during the first year was 4.1% (95% CI: 1.9-6.3%) and 1.7% (95% CI: 0.9-2.4%) per year thereafter. At the last follow-up before recurrent stroke or end of study, 117 RLS-positive patients (33.3%) had received a PDC, 154 (43.9%) were receiving antiplatelets, 63 (17.9%) received anticoagulation, and 17 (4.8%) received none of the above. No association with recurrent stroke was found for the secondary preventive regime.

Conclusion: Our multicenter hospital-based cohort study confirmed low recurrent event rates in RLS patients with otherwise cryptogenic stroke or TIA, as well as a great heterogeneity of current management. Despite the lack of scientific evidence, a substantial number of RLS-positive patients underwent PDC for secondary stroke prevention.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anticoagulants / therapeutic use*
  • Cardiac Catheterization* / instrumentation
  • Coronary Circulation*
  • Female
  • Follow-Up Studies
  • Foramen Ovale, Patent / complications
  • Foramen Ovale, Patent / mortality
  • Foramen Ovale, Patent / physiopathology
  • Foramen Ovale, Patent / therapy*
  • Germany
  • Humans
  • Ischemic Attack, Transient / etiology
  • Ischemic Attack, Transient / mortality
  • Ischemic Attack, Transient / physiopathology
  • Ischemic Attack, Transient / therapy*
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Proportional Hazards Models
  • Risk Assessment
  • Risk Factors
  • Secondary Prevention
  • Stroke / etiology
  • Stroke / mortality
  • Stroke / physiopathology
  • Stroke / therapy*
  • Time Factors
  • Treatment Outcome

Substances

  • Anticoagulants
  • Platelet Aggregation Inhibitors